Compounds > domiodol
Page last updated: 2024-11-06

domiodol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

domiodol: RN given refers to cpd with unspecified stereochemistry [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID43814
CHEMBL ID2106471
CHEBI ID134992
SCHEMBL ID19352
MeSH IDM0090193

Synonyms (46)

Synonym
domiodol
mg-13608
mucolitico maggioni
domiodol (usan)
D03888
61869-07-6
2-(iodomethyl)-1,3-dioxolane-4-methanol
mucolitico
m.g. 13608
domiodol [usan:inn]
domiodolum [inn-latin]
brn 5327600
1,3-dioxolane-4-methanol, 2-(iodomethyl)-
2-iodomethyl-4-hydroxymethyl-1,3-dioxolane
cis,trans-4-hydroxymethyl-2-iodomethyl-1,3-dioxolane
2-(iodomethyl)-dioxolane-4-methanol
domiodolum [latin]
dioxolane-4-methanol, 2-(iodomethyl)-
mg 13608
2-jodmethyl-4-hydroxymethyl-1,3-dioxolan [german]
CHEBI:134992
[2-(iodomethyl)-1,3-dioxolan-4-yl]methanol
cis,trans-4-idrossimetil-2-iodometil-1,3-diossolano
(e,z)-2-(iodomethyl)-1,3-dioxolane-4-methanol
niosh/ji1300000
JI13000000
cis,trans-4-idrossimetil-2-iodometil-1,3-diossolano [italian]
1,3-dioxolane-4-methanol, 2-(iodomethyl)-, (e,z)-
2-iodometil-4-idrossimetil-1,3-diossolano [italian]
2-iodometil-4-idrossimetil-1,3-diossolano
domiodolum
unii-c1pxf8v06n
c1pxf8v06n ,
2-jodmethyl-4-hydroxymethyl-1,3-dioxolan
CHEMBL2106471
SCHEMBL19352
domiodol [mi]
domiodol [inn]
domiodol [who-dd]
domiodol [mart.]
domiodol [usan]
NEIPZWZQHXCYDV-UHFFFAOYSA-N
DTXSID20866887
Q3713378
DB13768
domiodol; mg 13608

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dioxolane
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (77.78)18.7374
1990's1 (11.11)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.72 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (40.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ambroxol
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.		6.9610aromatic amine
bromhexine
Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744). bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).		6.9610organobromine compound;
substituted aniline;
tertiary amino compound		mucolytic
erythrosine
Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.		1.9610
n-vinyl-2-pyrrolidinone
N-vinyl-2-pyrrolidinone: monomer of POVIDONE; structure given in first source		2.2510pyrrolidin-2-ones
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		1.9610acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
oseltamivir
Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.		2.2510acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
vinblastine
sobrerol: RN given is for parent cpd; structure		3.7521p-menthane monoterpenoid
carbocysteine
Carbocysteine: A compound formed when iodoacetic acid reacts with sulfhydryl groups in proteins. It has been used as an anti-infective nasal spray with mucolytic and expectorant action.. S-carboxymethyl-L-cysteine : An L-cysteine thioether that is L-cysteine in which the hydrogen of the thiol group has been replaced by a carboxymethyl group.		3.3411L-cysteine thioether;
non-proteinogenic L-alpha-amino acid		mucolytic
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		2.2510macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		8.3411cysteiniumfundamental metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Infections, Coronavirus
[description not available]		02.2510
2019 Novel Coronavirus Disease
[description not available]		02.2510
Pneumonia, Viral
Inflammation of the lung parenchyma that is caused by a viral infection.		02.2510
Coronavirus Infections
Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).		02.2510
Asthma, Bronchial
[description not available]		01.9610
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		01.9610
Bronchitis
Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.		01.9610
Obstructive Lung Diseases
[description not available]		03.3411
Lung Diseases, Obstructive
Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.		03.3411
Bronchial Pneumonia
[description not available]		03.3411
Cough
A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.		04.3222
Breathlessness
[description not available]		03.3611
Complication, Postoperative
[description not available]		03.3611
Dyspnea
Difficult or labored breathing.		03.3611
Postoperative Complications
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.		03.3611